This event will discuss in detail viewpoints from various payers, HTAs, patient groups on the definition, measurement, validation and value of achieving various QOL improvements in several therapeutic areas. Furthermore, there will also be perspectives from the pharma industry of how they overcame challenges in researching and demonstrating QOL improvements to provide extra value to payers, physicians and patients. 3 EVENTS IN ONE Achieving Economic & Clinical Outcomes for Market Access Day 1 - Day 2 (am) - May 6th/7th, 2013 This event offers the ideal opportunity to increase your understanding of these changes and benefit from the updated content discussed.  Designing short or long term endpoints that matter to regulatory & payer representatives in your region is key to the success of your market access. This event will be a perfect learning curve and networking tool for anyone looking to understand and meet regulatory and payer determined endpoints. 4th Annual Oncology Health Outcomes & Market Access  Day 2 (pm) - 3: Stream 1 - May 7th/8th, 2013 This event will uniquely look at how to generate quality evidence and demonstrate value to global payers health technology assessors and other key stakeholders for higher-cost oncology therapeutics. Such drugs may include niche cancer biologics, expensive oncology small molecules, orphan drugs, personalized medicines or biosimilars. This event will look at overcoming the challenge to generate strong evidence to demonstrate value, the latest innovative market access techniques specific to oncology, satisfying HTA requirements to build the right dossier.  Demonstrating Quality of Life Outcomes to HTAs & Payers Day 2 (pm) - 3: Stream 2 - May 7th/8th, 2013 This event will discuss in detail viewpoints from various payers, HTAs, patient groups on the definition, measurement, validation and value of achieving various QOL improvements in several therapeutic areas.  Furthermore, there will also be perspectives from the pharma industry of how they overcame challenges in researching and demonstrating QOL improvements to provide extra value to payers, physicians and patients.